Clinical applications of attenuated MVA poxvirus strain

被引：61

作者：

Elena Gomez, Carmen ^{[1
]}

Perdiguero, Beatriz ^{[1
]}

Garcia-Arriaza, Juan ^{[1
]}

Esteban, Mariano ^{[1
]}

机构：

[1] CSIC, Ctr Nacl Biotecnol, Dept Mol & Cellular Biol, Madrid, Spain

来源：

EXPERT REVIEW OF VACCINES | 2013年 / 12卷 / 12期

关键词：

cancer; clinical trials; infectious diseases; modified vaccinia virus Ankara; vaccines; vector improvements; VACCINIA VIRUS ANKARA; T-CELL RESPONSES; ANTIGEN; 5T4; TROVAX; PRIME-BOOST IMMUNIZATION; METASTATIC RENAL-CANCER; YELLOW-FEVER VACCINE; HIV-1 DNA VACCINE; TUBERCULOSIS VACCINE; MYCOBACTERIUM-TUBERCULOSIS; IMMUNE-RESPONSES;

D O I：

10.1586/14760584.2013.845531

中图分类号：

R392 [医学免疫学]; Q939.91 [免疫学];

学科分类号：

100102 ;

摘要：

The highly attenuated poxvirus strain modified vaccinia virus Ankara (MVA) has reached maturity as a vector delivery system and as a vaccine candidate against a broad spectrum of diseases. This has been largely recognized from research on virus-host cell interactions and immunological studies in pre-clinical and clinical trials. This review addresses the studies of MVA vectors used in phase I/ II clinical trials, with the aim to provide the main findings obtained on their behavior when tested against relevant human diseases and cancer and also highlights the strategies currently implemented to improve the MVA immunogenicity. The authors assess that MVA vectors are progressing as strong vaccine candidates either alone or when administered in combination with other vectors.

引用

页码：1395 / 1416

页数：22

共 178 条

[51] Uptake of antigens from modified vaccinia Ankara virus-infected leukocytes enhances the immunostimulatory capacity of dendritic cells [J].

Flechsig, Christin ;

Suezer, Yasemin ;

Kapp, Markus ;

Tan, Sen Mui ;

Loeffler, Juergen ;

Sutter, Gerd ;

Einsele, Hermann ;

Grigoleit, Goetz Ulrich .

CYTOTHERAPY, 2011, 13 (06) :739-752

[52] ACTIVATION OF TUBERCULOSTATIC MACROPHAGE FUNCTIONS BY GAMMA-INTERFERON, INTERLEUKIN-4, AND TUMOR-NECROSIS-FACTOR [J].

FLESCH, IEA ;

KAUFMANN, SHE .

INFECTION AND IMMUNITY, 1990, 58 (08) :2675-2677

[53] Immunology of tuberculosis [J].

Flynn, JL ;

Chan, J .

ANNUAL REVIEW OF IMMUNOLOGY, 2001, 19 :93-129

[54] TUMOR-NECROSIS-FACTOR-ALPHA IS REQUIRED IN THE PROTECTIVE IMMUNE-RESPONSE AGAINST MYCOBACTERIUM-TUBERCULOSIS IN MICE [J].

FLYNN, JL ;

GOLDSTEIN, MM ;

CHAN, J ;

TRIEBOLD, KJ ;

PFEFFER, K ;

LOWENSTEIN, CJ ;

SCHREIBER, R ;

MAK, TW ;

BLOOM, BR .

IMMUNITY, 1995, 2 (06) :561-572

[55] Multifunctional, high-level cytokine-producing Th1 cells in the lung, but not spleen, correlate with protection against Mycobacterium tuberculosis aerosol challenge in mice [J].

Forbes, Emily K. ;

Sander, Clare ;

Ronan, Edward O. ;

McShane, Helen ;

Hill, Adrian V. S. ;

Beverley, Peter C. L. ;

Tchilian, Elma Z. .

JOURNAL OF IMMUNOLOGY, 2008, 181 (07) :4955-4964

[56] A Heterologous Prime/Boost Vaccination Strategy Enhances the Immunogenicity of Therapeutic Vaccines for Hepatitis C Virus [J].

Fournillier, Anne ;

Frelin, Lars ;

Jacquier, Emilie ;

Ahlen, Gustaf ;

Brass, Anette ;

Gerossier, Estelle ;

Holmstrom, Fredrik ;

Broderick, Kate E. ;

Sardesai, Niranjan Y. ;

Bonnefoy, Jean-Yves ;

Inchauspe, Genevieve ;

Sallberg, Matti .

JOURNAL OF INFECTIOUS DISEASES, 2013, 208 (06) :1008-1019

[57] Differences in virus-induced cell morphology and in virus maturation between MVA and other strains (WR, Ankara, and NYCBH) of vaccinia virus in infected human cells [J].

Gallego-Gómez, JC ;

Risco, C ;

Rodríguez, D ;

Cabezas, P ;

Guerra, S ;

Carrascosa, JL ;

Esteban, M .

JOURNAL OF VIROLOGY, 2003, 77 (19) :10606-10622

[58] Deletion of Specific Immune-Modulatory Genes from Modified Vaccinia Virus Ankara-Based HIV Vaccines Engenders Improved Immunogenicity in Rhesus Macaques [J].

Garber, David A. ;

O'Mara, Leigh A. ;

Gangadhara, Sailaja ;

McQuoid, Monica ;

Zhang, Xiugen ;

Zheng, Rui ;

Gill, Kiran ;

Verma, Meena ;

Yu, Tianwei ;

Johnson, Brent ;

Li, Bing ;

Derdeyn, Cynthia A. ;

Ibegbu, Chris ;

Altman, John D. ;

Hunter, Eric ;

Feinberg, Mark B. .

JOURNAL OF VIROLOGY, 2012, 86 (23) :12605-12615

[59] Expanding the Repertoire of Modified Vaccinia Ankara-Based Vaccine Vectors via Genetic Complementation Strategies [J].

Garber, David A. ;

O'Mara, Leigh A. ;

Zhao, Jun ;

Gangadhara, Sailaja ;

An, InChul ;

Feinberg, Mark B. .

PLOS ONE, 2009, 4 (05)

[60] Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pot and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02) [J].

Garcia, Felipe ;

Lopez Bernaldo de Quiros, Juan Carlos ;

Gomez, Carmen E. ;

Perdiguero, Beatriz ;

Najera, Jose L. ;

Jimenez, Victoria ;

Garcia-Arriaza, Juan ;

Guardo, Alberto C. ;

Perez, Inaki ;

Diaz-Brito, Vicens ;

Sanchez Conde, Matilde ;

Gonzalez, Nuria ;

Alvarez, Amparo ;

Alcami, Jose ;

Luis Jimenez, Jose ;

Pich, Judit ;

Albert Arnaiz, Joan ;

Maleno, Maria J. ;

Leon, Agathe ;

Angeles Munoz-Fernandez, Maria ;

Liljestrom, Peter ;

Weber, Jonathan ;

Pantaleo, Giuseppe ;

Gatell, Jose M. ;

Plana, Montserrat ;

Esteban, Mariano .

VACCINE, 2011, 29 (46) :8309-8316

← 1 2 3 4 5 6 7 8 9 10 →